NCT05891158
A Study About Fazirsiran in People With and Without Liver Problems
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Results posted: Nov 16, 2026
Notable Results first posted: Nov 16, 2026 Show 4 more changesShow less
- Eligibility criteria shortened, about 9 words
- Primary endpoints revised (3)
- Study sites: 4 to 3
- Secondary endpoints revised (15)
- Minor Start date: Oct 6, 2023 to Oct 5, 2023v11
- Minor Start date: Oct 5, 2023 to Oct 6, 2023v10
- Minor Trial status: Active, Not Recruiting to Completed
- Primary and study completion dates changed from estimate of Sep 15, 2025 to Sep 3, 2025
Show 7 earlier versionsHide 7 earlier versions
- Minor Primary and study completion dates: Apr 15, 2025 to Sep 15, 2025v8
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 41 to confirmed 34
- Site details revised at 4 of 4 sites
- Notable Eligibility criteria expanded, about 105 wordsv6
- Minor Primary and study completion dates: Feb 15, 2025 to Apr 15, 2025v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Sep 25, 2023 to Oct 5, 2023
- Site details revised at 4 of 4 sites
- Notable Start date: Jul 24, 2023 to Sep 25, 2023
- Primary and study completion dates: Dec 15, 2024 to Feb 15, 2025
- Minor Study sites: 2 to 4v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (15)
Show 10 moreShow less
Arms and interventions
Participants with mild hepatic impairment (HI) will receive fazirsiran 200 milligrams (mg) subcutaneous (SC) injection on Day 1.
Participants with moderate HI will receive fazirsiran 200 mg SC injection on Day 1. The dose may be modified after review of available safety and PK data by the sponsor study team in consultation with the investigator.
Participants with severe HI will receive fazirsiran 200 mg SC injection on Day 1. The dose may be modified after review of available safety and PK data by the sponsor study team in consultation with the investigator.
Participants with normal hepatic function will receive fazirsiran 200 mg SC injection on Day 1. The dose may be modified after review of available safety and PK data by the sponsor study team in consultation with the investigator.
Drugs: Fazirsiran
Sites
3 sites in 2 countries
Slovakia 2, Hungary 1